Newsroom

Sorted by: Latest

-

Resumen: Armis Centrix™ fue nombrada “Mejor solución” para la gestión de la exposición cibernética; Armis también fue ganadora de múltiples premios Global InfoSec en RSAC 2026

SAN FRANCISCO--(BUSINESS WIRE)--Armis, la empresa de gestión de la exposición y seguridad cibernética, anunció hoy que ha ganado múltiples premios Global InfoSec otorgados por Cyber Defense Magazine, en la edición de este año de la conferencia RSAC™. Armis recibió los siguientes reconocimientos: Armis Centrix™ ganó el premio a la “Mejor solución” para la gestión de la exposición cibernética Armis fue nombrada “Empresa de ciberseguridad elegida por el editor” Yevgeny Dibrov, CEO y cofundador de...
-

Kinaxis Reconhecida como Líder nos Relatórios da Gartner® Magic Quadrant™ de 2026 para Planejamento da Cadeia de Fornecimento

OTTAWA, Ontário--(BUSINESS WIRE)--Kinaxis® Inc. (TSX: KXS), líder mundial em orquestração da cadeia de fornecimento anunciou hoje que foi posicionada como Líder na Gartner® Magic Quadrant™ de 2026 para Soluções de Planejamento da Cadeia de Fornecimento para Setores Discretos e na Gartner® Magic Quadrant™ de 2026 para Soluções de Planejamento da Cadeia de Fornecimento para Setores de Processo. Em ambos os relatórios, a Gartner reconheceu a Kinaxis por sua capacidade de execução e abrangência de...
-

Peakstone Realty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Peakstone Realty Trust - PKST

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Peakstone Realty Trust (NYSE: PKST) to Brookfield Asset Management (NYSE: BAM). Under the terms of the proposed transaction, shareholders of Peakstone will receive $21.00 in cash for each share of Peakstone that they own. KSF is seeking to determine whether this consideration and the process that le...
-

Armis Centrix™ désignée « Meilleure solution » pour la gestion de l'exposition aux cybermenaces, alors qu'Armis remporte de nombreux prix internationaux en sécurité de l'information à la conférence RSAC 2026

SAN FRANCISCO--(BUSINESS WIRE)--Armis, société spécialisée dans la gestion de l'exposition aux cybermenaces et la sécurité, a annoncé aujourd'hui avoir remporté plusieurs Global InfoSec Awards décernés par le magazine Cyber Defense lors de la conférence RSAC™ de cette année. Armis a reçu les distinctions suivantes : Armis Centrix™ a remporté le prix de la « Meilleure solution » pour la gestion de l'exposition aux cybermenaces Armis nommée « Entreprise de cybersécurité choisie par les éditeurs »...
-

The Fundrise Innovation Fund (VCX) Invests in Erebor Bank

WASHINGTON--(BUSINESS WIRE)--The Fundrise Innovation Fund (VCX) has announced a new investment in Erebor Bank, a newly chartered national bank built from the ground up to serve the technology industry. Founded by Palmer Luckey, the co-founder of Oculus VR and Anduril Industries, Erebor is designed to serve startups, technology companies, and the individuals who work at and invest in them. The bank aims to fill a gap in the market left by the collapse of Silicon Valley Bank in 2023, which had be...
-

Samenvatting: Kinaxis erkend als Leader in de 2026 Gartner® Magic Quadrant™-reports voor Supply Chain Planning

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX: KXS), een wereldleider in orkestratie van de toeleveringsketen, maakte vandaag bekend dat het bedrijf als Leader werd gepositioneerd, zowel in de 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions for Discrete Industries als in de 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions for Process Industries. In beide reports erkende Gartner Kinaxis voor haar vermogen om uit te voeren en de volledigheid van de visie....
-

Tri Pointe Homes Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tri Pointe Homes, Inc. - TPH

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tri Pointe Homes, Inc. (NYSE: TPH) to Sumitomo Forestry Co., Ltd. Under the terms of the proposed transaction, shareholders of Tri Pointe will receive $47.00 in cash for each share of Tri Pointe that they own. KSF is seeking to determine whether this consideration and the process that led to it...
-

SunOpta Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SunOpta Inc. - STKL

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SunOpta Inc. (NasdaqGS: STKL) to Refresco. Under the terms of the proposed transaction, shareholders of SunOpta will receive $6.50 in cash for each share of SunOpta that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the...
-

Udemy Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Udemy, Inc. - UDMY

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Udemy, Inc. (NasdaqGS: UDMY) to Coursera, Inc. (NYSE: COUR). Under the terms of the proposed transaction, shareholders of Udemy will receive 0.800 shares of Coursera common stock for each share of Udemy that they own. KSF is seeking to determine whether this consideration and the process that l...
-

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s growing inflammation portfolio. OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously admi...